11-valent recombinant HPV vaccine / Sinopharm - LARVOL DELTA

A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years (clinicaltrials.gov) - P3 | N=13500 | Recruiting | Sponsor: National Vaccine and Serum Institute, China | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Oncology

Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) (clinicaltrials.gov) - P2 | N=480 | Completed | Sponsor: National Vaccine and Serum Institute, China | Active, not recruiting ➔ Completed

Trial completion • Cervical Cancer • Infectious Disease • Oncology • Solid Tumor